Dexlansoprazole MR

Bibliography

• Katz PO, Scheiman JM, Barkun AN. Review article: acid-related disease-what are the unmet clinical needs? Aliment Pharmacol Ther 2006;23(2):9-22
   PubMed Web of Science ®Google Scholar
• Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease- where next? Aliment Pharmacol Ther 2005;22(2):79-94
   PubMed Web of Science ®Google Scholar
• Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 2005;22(3):10-19
   PubMedGoogle Scholar
• Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in Primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10(2):119-24
   PubMed Web of Science ®Google Scholar
• Feldman M. Gastric Secretion. In Sleisenger & Fordtran's gastrointestinal and liver disease. 8th edition. Philadelphia, PA: Saunders Elsevier; 2006
   Google Scholar
• Sachs G, Shin JM, Briving C, et al. The pharmacology of the gastric acid pump: the H+, K+ ATPase. Ann Rev Pharmacol Toxicol 1995;35:277-305
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006;23(2):2-8
   PubMed Web of Science ®Google Scholar
• Tonini M, DeGiorgio R, DePonti F. Novel therapeutic strategies in acid-related disorders. Expert Opin Ther Patents 2003;13(5):639-49
   Web of Science ®Google Scholar
• Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000;14(12):1595-603
   PubMed Web of Science ®Google Scholar
• Bate CM, Booth SN, Crowe JP, et al. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther 1993;7(5);501-7
   PubMedGoogle Scholar
• Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996;91(8):1532-8
   PubMed Web of Science ®Google Scholar
• Abelo A, Andersson TB, Antonsson M, et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000;28(8):966-72
   PubMed Web of Science ®Google Scholar
• Miner P, Katz P, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98(12):2616-20
   PubMed Web of Science ®Google Scholar
• Vakily M, Zhang W, Wu J, et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials *. Curr Med Res Opin 2009;25:627-38
   PubMed Web of Science ®Google Scholar
• Kapidex package insert. (Takeda Global Research & Development Center, Inc)
   Google Scholar
• Wu J, Vakily M, Witt G, et al. TAK-390 MR vs. Lansoprazole (LAN) for maintenance of drug concentration above a threshold which corresponds to higher%-time pH>4. Am J Gastroenterol 2007;102(Suppl 2):124. (ID 55076)
   Google Scholar
• Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of Dexlansoprazole MR. A novel approach to outcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009;29(9):928-37
   PubMed Web of Science ®Google Scholar
• Czerniak R, Vakily M, Wu J. TAK-390 MR, a novel dual delayed release formulation of a PPI, is bioequivalent when administered as granules sprinkled over applesauce or as an intact capsule. Am J Gastroenterol 2008;103 (Suppl S):S4-5. (ID: 58627)
   Web of Science ®Google Scholar
• Grabowski B, Lee R, Czerniak R. Metabolism and excretion of (14 C) TAK-390 in healthy male subjects. Drug Metab Rev 2008;40(Suppl 3):194-5
   Google Scholar
• Lee RD, Vakily M, Mulford D, et al. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor–evidence for dosing flexibility. Aliment Pharmacol Ther 2009;29:824-33
   PubMed Web of Science ®Google Scholar
• Vakily M, Lee RD, Wu J, et al. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig 2009;29:35-50
   PubMed Web of Science ®Google Scholar
• Vakily M, Zhang W, Wu J, Mulford D. Effect of age and gender on the pharmacokinetics of a single oral dose of TAK-390 MR (modified release). Clin Pharmacol Ther 2008;83(Suppl 1):96
   Google Scholar
• Lee RD, Wu J, Vakily D, Mulford D. Effect of hepatic impairment on the pharmacokinetics of TAK-390 MR (modified release). Clin Pharmacol Ther 2008;83(Suppl 1)
   Google Scholar
• Zhang W, Wu J, Atkinson SN. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin Pharmacol 2009;49(4):444-54
   PubMed Web of Science ®Google Scholar
• Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment Pharmacol Ther 2009;29:731-41
   PubMed Web of Science ®Google Scholar
• Shaheen N, Peura D, Perez MC, et al. Impact of baseline LA grade on healing on healing of erosive esophagitis (EE) following treament with TAK-390 MR, a proton pump inhibitor (PPI) with a novel dual delayed release formulation, compared with lansoprazole. Am J Gastroenterol 2008;103(1):S10-1
   Google Scholar
• Metz DC, Howden CW, Perez MC, et al. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009;29:742-54
   PubMed Web of Science ®Google Scholar
• Howden C, Larson L, Palmer R, Perez MC. Placebo controlled trial of 2 doses of TAK-390 MR a PPI with novel dual delayed release technology as maintenance treatment for patients with healed erosive esophagitis. Am J Gastroenterol 2008;103(1):abstract 13
   PubMedGoogle Scholar
• Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with nonerosive reflux disease. Aliment Pharmacol Ther 2009;29(12):1261-72
   PubMed Web of Science ®Google Scholar
• Vakily M, Jingtao WU, Stuart N, et al. Lack of electrocardiographic effect of Dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor Dexlansoprazole in healthy subjects. J Clin Pharmacol 2009. In Press
   PubMedGoogle Scholar